Apotex, Inc. v. Cephalon, Inc.

MEMORANDUM OPINION

Goldberg, District Judge

This antitrust ease involves allegations that four reverse-payment settlement agreements entered into by a brand-name drug manufac*224turer and four generic drug companies constitute antitrust violations under the Sherman Act.1 Apotex, Inc,, a generic competitor, and other Plaintiffs claim that these settlement agreements were created and signed with the purpose of delaying the market entry of generic versions of the brand-name pharmaceutical, Provigil. Defendants maintain that the agreements were legitimate settlements of Hatch-Waxman patent litigation…